Dr. Salem Baldi | Cancer Diagnosis | Best Researcher Award

Posted on by Pencis

Dr. Salem Baldi | Cancer Diagnosis | Best Researcher Award

Shaoyang University | China

Author Profile

Scopus

ORCID ID

Google Scholar

🌍Dr. Salem Baldi, Ph.D.
Associate Professor, Medical Laboratory Diagnostics🔬:

🧬Biography:

Dr. Salem Baldi is an esteemed Associate Professor at the Department of Medical Laboratory Diagnostics, Shaoyang University, China. With a strong background in biochemistry, molecular biology, and clinical diagnostics, he has made noteworthy contributions to cancer research and genetic diagnostics 🧬. He previously worked as a Biochemistry Research Scientist at Anxuyuan Biotechnology in Shenzhen, where he applied his expertise in molecular diagnostics.

Dr. Baldi holds a Ph.D. in Clinical Laboratory Diagnostics from Dalian Medical University and a Master’s in Molecular Genetics from Jiamusi University, China. His research expertise spans cancer cell biology, DNA library preparation, and advanced genetic techniques such as CRISPR/Cas9 for disease modeling. 🧫

Fluent in English, Arabic, and Chinese, Dr. Baldi is deeply engaged in the global scientific community, holding memberships in the European Society for Blood and Marrow Transplantation and the Arab Society of Genetic Counselors. His remarkable dedication to science has earned him numerous awards, recognizing his impact in both academic and scientific circles. 🏅

Beyond his professional life, Dr. Baldi enjoys soccer, badminton, tennis, traveling, reading, and gardening ⚽🌿📚.

🧪Research Interests:

  • Cancer Diagnostics 🧫
  • Molecular Genetics 🧬
  • Clinical Laboratory Science 🧪
  • Innovative Approaches in Medical Research 🌱

📊Skills & Expertise:

  • Mammalian Cell Culture (Primary and Cancer Cells)
  • Molecular Cloning, Transfection, Gene Expression
  • PCR, qPCR, Real-Time PCR 🔬
  • Western Blotting, SDS-PAGE, Immunofluorescence
  • DNA Library Preparation (NGS, Illumina, PacBio) 📊
  • CRISPR/Cas9 Disease Modeling 🧬

🏅Awards & Recognitions:

  • 2021: Excellence in Scientific Research 🏅, Yemeni Ministry of Higher Education
  • 2022: Certificate of Gratitude 🙏, Yemeni Students Union, China

🌍Languages:

  • English
  • Arabic
  • Chinese

✨Conclusion:

🌱Dr. Salem Baldi is a dedicated researcher and educator, committed to advancing the field of medical laboratory diagnostics. His expertise in molecular biology and biochemistry, coupled with a global perspective and fluency in multiple languages, positions him as a leader in cancer research and diagnostics. His passion for integrating traditional and modern medical practices drives his innovative approach to improving patient outcomes. Beyond the lab, his diverse interests reflect a well-rounded individual who is deeply engaged in both his personal and professional pursuits. ✨

📊🔬NOTABLE PUBLICATION:

  • Surgery improves survival in bladder signet-ring cell carcinoma-a population-based study
    Authors: Alradhi, M., Safi, M., Tao, S., Baldi, S., Li, X.
    Journal: Therapeutic Advances in Urology
    Year: 2022

 

  • Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study
    Authors: Al-Danakh, A., Safi, M., Alradhi, M., Zhu, X., Yang, D.
    Journal: Cells
    Year: 2022

 

  • ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression
    Authors: Baldi, S., Zhang, Q., Zhang, Z., Al-Nusaif, M., Zuo, Y.
    Journal: Journal of Cellular and Molecular Medicine
    Year: 2022

 

  • Novel characterization discoveries of ferroptosis-associated molecules in COAD microenvironment based TCGA data
    Authors: Baldi, S., He, Y., Ivanov, I., Gao, Y., Tian, H.
    Journal: Frontiers in Molecular Biosciences
    Year: 2022

 

  • Unraveling the salt tolerance of Phi29 DNA polymerase using compartmentalized self-replication and microfluidics platform
    Authors: Sun, Y., Ko, D.H., Gao, J., He, Y., Tian, H.
    Journal: Frontiers in Microbiology
    Year: 2023

Dr. Pengchong Wang | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Dr. Pengchong Wang | Cancer Therapy | Best Researcher Award

Shaanxi Provincial People’s Hospital | China

AUTHOR PROFILE

Scopus

💊 WANG PENGCHONG: ACADEMIC PROFILE AND ACHIEVEMENTS 🎓

🎓EARLY ACADEMIC PURSUITS 📚

Wang Pengchong, the Chief Pharmacist at Shaanxi Provincial People’s Hospital, earned his PhD in Pharmacy from Xi’an Jiaotong University. His academic journey was shaped by a focus on tumor pharmacy and targeted drug delivery systems. His early years were spent delving into the intricacies of pharmaceutical care, particularly in the context of oncology, laying the foundation for his future breakthroughs.

💼 PROFESSIONAL ENDEAVORS 🏥

Wang is a dedicated member of the Pharmaceutical Care Committee of the Shaanxi Pharmacological Society. His professional work has revolved around tumor pharmacology, pioneering approaches to targeted cancer treatments. He has played an instrumental role in several major projects, including three general projects funded by the National Natural Science Foundation of China and two key R&D projects in Shaanxi Province. His leadership in high-profile initiatives highlights his influence on pharmaceutical advancements.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS 🎯

Wang Pengchong’s research is centered on targeted drug delivery systems and tumor pharmacy research. His contributions are geared toward improving cancer therapies by focusing on precision medicine, which minimizes side effects and enhances the effectiveness of treatment. His work extends into innovative methods, such as nanotechnology in drug targeting. Wang has led multiple significant projects, including the Shaanxi Province Science and Technology Plan Project, the Xi’an City Science and Technology Plan Project, and the Yaodong Shenzhou Pharmaceutical Research Capacity Building Project.

✨ IMPACT AND INFLUENCE 🌐

Wang’s research has had a profound impact on cancer treatment strategies and pharmaceutical care. His efforts have advanced both the scientific understanding and practical application of cancer drugs, particularly in how they can be precisely targeted to tumor cells while sparing healthy tissues. Through his leadership in government-backed research initiatives, Wang has become a driving force in the field, influencing not just Shaanxi Province but the broader pharmaceutical landscape.

📊 ACADEMIC CITES 📄

In the past five years, Wang Pengchong has published more than ten SCI-indexed papers in international journals. His work is widely cited, particularly in oncology and pharmaceutical sciences. His research topics span from cutting-edge drug delivery systems to therapeutic advancements, solidifying his reputation in the global scientific community.

🌍 LEGACY AND FUTURE CONTRIBUTIONS 🏆

Wang Pengchong’s legacy will continue to grow as he contributes to targeted cancer therapies and pharmaceutical innovations. His role in advancing precision medicine ensures that his work will influence the next generation of cancer treatments. By leading critical projects and setting new benchmarks in oncology pharmacy, Wang is shaping the future of drug delivery systems and cancer care. His ongoing commitment to pharmaceutical research guarantees that his contributions will leave a lasting impact on the field.

📈 CONCLUSION 🌟

Wang Pengchong’s distinguished career as a Chief Pharmacist and researcher has made significant strides in the fields of targeted drug delivery systems and tumor pharmacy. His academic foundation, coupled with leadership in high-impact research projects, has not only advanced cancer treatment but also positioned him as a key contributor to pharmaceutical sciences. With over a decade of impactful publications and successful project leadership, Wang’s research continues to shape the future of oncology treatments, fostering innovations that will benefit patients worldwide. His work embodies a lasting legacy of precision medicine and cutting-edge cancer therapies, ensuring he remains a pivotal figure in pharmaceutical research and development. 🌍🔬

 

📊🔬NOTABLE PUBLICATION:

 

    • Mucoadhesive nanoparticles-based oral drug delivery systems enhance ameliorative effects of low molecular weight heparin on experimental colitis
      • Authors: Yan, Y., Sun, Y., Wang, P., Xing, J., Dong, Y.
      • Journal: Carbohydrate Polymers
      • Year: 2020

     

    • An improved synthesis of water-soluble dual fluorescence emission carbon dots from holly leaves for accurate detection of mercury ions in living cells
      • Authors: Wang, P., Yan, Y., Zhang, Y., Xing, J., Dong, Y.
      • Journal: International Journal of Nanomedicine
      • Year: 2021

     

    • One-pot synthesis of nuclear targeting carbon dots with high photoluminescence
      • Authors: Wang, P., Ji, H., Guo, S., Xing, J., Dong, Y.
      • Journal: Chinese Chemical Letters
      • Year: 2021

     

    • Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis
      • Authors: Wang, P., Zhang, Y., Lei, H., Xing, J., Dong, Y.
      • Journal: Carbohydrate Polymers
      • Year: 2023

     

    • Multifunctional nanosystems sequentially regulating intratumor Fenton chemistry by remodeling the tumor microenvironment to reinforce chemodynamic therapy
      • Authors: Dong, K., Chen, W., Zhao, Z., Lu, T., Dong, Y.
      • Journal: Biomaterials Advances
      • Year: 2022

Dr Ghanshyam Ghelani | Bladder Cancer | Best Researcher Award

Posted on by Pencis

Dr Ghanshyam Ghelani | Bladder Cancer | Best Researcher Award

SUNY Upstate Medical University | United States 

Author Profile

Scopus

ORCID Id

🩺Ghanshyam Ghelani, MD 💉

Hematology-Oncology Fellow & Clinical Investigator
SUNY Upstate Medical University, Syracuse, NY

🎓 Education

  • M.B.B.S. – B.J. Medical College, Ahmedabad, Gujarat, India (09/2002 – 03/2008)
    📚 Ranked in the top 10% of a class of 250 students.
  • Internal Medicine Residency – The Wright Center for Graduate Medical Education, Scranton, PA, USA (07/2013 – 06/2016)
    🏥 Completed residency at affiliate hospitals including Geisinger CMC and VA Medical Center.
    🏅 Awarded M.D. by New York State on November 16, 2016.
  • Hematology-Oncology Fellowship – SUNY Upstate Medical University, Syracuse, NY (07/2021 – 06/2024)
    💉 Active Member of the Transfusion Medicine Committee and Hematology-Oncology Representative of the Resident and Fellow Forum.

💼 Certifications and Licensure

  • Board Certification – The American Board of Internal Medicine
  • State License – New York: Full License # 285166
  • DEA Registration – FG6123385
  • Advanced Cardiac Life Support (ACLS) – Re-Certified on 10/09/2021

🌐 Professional Memberships

  • 👨‍⚕️ Member, American College of Physicians
  • 🇮🇳 Life Member, Gujarat Medical Council
  • 🩺 Member, American Medical Association (AMA)
  • 🧬 Member, American Society of Clinical Oncology (ASCO)
  • 🌍 Member, European Society for Medical Oncology (ESMO)
  • 🩸 Member, American Society of Hematology (ASH)

🔬 Research and Academic Work

Assistant Professor of Medicine & Clinical Investigator
SUNY Upstate Medical University (07/2016 – 06/2021)

  • Key Research Projects
    • 🧬 HPV-Positive Clinically Advanced Bladder Squamous Cell Carcinoma (aBSCC): Analyzed genomic alterations associated with HPV.
    • 🧑‍🔬 Metabolic Syndrome & Immunotherapy in NSCLC: Studied the impact of metabolic syndrome on outcomes with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).
    • 🩸 Peripheral Blood Biomarkers in Metastatic Melanoma: Identified biomarkers for treatment response and immune-related adverse events in patients treated with immunotherapy for stage-IV melanoma.

🏅 Awards

  • Ranked in the top 10% of the class during medical school. 🎖️

Dr. Ghanshyam Ghelani is a dedicated Hematology-Oncology fellow with expertise in internal medicine and a strong background in cancer research, particularly in genomic profiling, immunotherapy, and biomarker discovery. 🧬💡

 

🔍 Conclusion

Dr. Ghanshyam Ghelani is a highly accomplished medical professional, currently advancing his expertise as a Hematology-Oncology Fellow at SUNY Upstate Medical University. With a strong foundation in internal medicine and an impressive portfolio of research in cancer treatment and immunotherapy, Dr. Ghelani has made significant contributions to the field of oncology. His active involvement in professional societies and dedication to exploring novel cancer therapies highlight his commitment to improving patient outcomes through cutting-edge research and clinical practice. Dr. Ghelani’s journey reflects a deep passion for medicine, research, and innovation in cancer care. 💉🧬🌟

 

📊🔬NOTABLE PUBLICATION:

 

    • Radioimmunoconjugates in the Age of Modern Immuno-Oncology
      • Authors: Nasr, D., Kumar, P.A., Zerdan, M.B., Graziano, S., Lim, S.H.
      • Journal: Life Sciences
      • Year: 2022

     

    • HPV-Positive Clinically Advanced Squamous Cell Carcinoma of the Urinary Bladder (aBSCC): A Comprehensive Genomic Profiling (CGP) Study
      • Authors: Ghelani, G.H., Zerdan, M.B., Jacob, J., Bratslavsky, G., Basnet, A.
      • Journal: Urologic Oncology: Seminars and Original Investigations
      • Year: 2023

     

    • Breast Cancer Treatment: To Target or Not? That Is the Question
      • Authors: Stone, A., Lin, K.M., Ghelani, G.H., Graziano, S., Kotula, L.
      • Journal: Cancers
      • Year: 2023

     

    • Hematologic Abnormalities After COVID-19 Infection: A Case of Coombs-Negative Hemolytic Anemia and Thrombocytopenia
      • Authors: Siegenthaler, A.G., Ghelani, G., Brady, A., Loon, T., Madhira, B.R.
      • Journal: Journal of Investigative Medicine High Impact Case Reports
      • Year: 2023

     

    • Metabolic Syndrome Is Independently Associated with Improved Overall Survival to First-Line Therapy with Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
      • Authors: Bou Zerdan, M., Ashok Kumar, P., Barrios, D.M., Graziano, S., Lim, S.H.
      • Journal: Frontiers in Oncology
      • Year: 2023

Assoc Prof Dr. Elcin Aydin | Endometrium Cancer | Best Researcher Award

Posted on by Pencis

Assoc Prof Dr. Elcin Aydin | Endometrium Cancer | Best Researcher Award

University of Health Sciences, Izmir | Turkey

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

  • Assoc Prof Dr. Elçin Aydın’s academic journey began with a strong foundation in medical sciences. She pursued her education with a focus on radiology, demonstrating a keen interest in the diagnostic and therapeutic applications of imaging technologies. Her early academic pursuits laid the groundwork for her specialization in abdominal and genitourinary radiology.

PROFESSIONAL ENDEAVORS

  • Dr. Aydın is currently affiliated with the University of Health Sciences in Izmir, Turkey, and works at Izmir City Hospital. Her professional endeavors have been marked by a commitment to clinical excellence and academic rigor. She has been an active member of prestigious organizations such as the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), the European Congress of Radiology (ECR), and the European Society of Urogenital Radiology (ESUR).

CONTRIBUTIONS AND RESEARCH FOCUS

  • Dr. Aydın has made significant contributions to the field of radiology through her research and clinical work. She has published 14 original articles in SCI-EXP indexed journals and authored 4 case studies, highlighting her expertise in abdominal and genitourinary radiology. Her research focuses on the diagnostic accuracy and clinical applications of imaging techniques in these areas, aiming to improve patient outcomes through advanced radiological practices.

IMPACT AND INFLUENCE

  • Through her scholarly publications and clinical practice, Dr. Aydın has had a considerable impact on the field of radiology. Her work is frequently cited by peers, reflecting the influence of her research on contemporary radiological practices. Her involvement in ESGAR, ECR, and ESUR underscores her influence within the radiological community, where she contributes to the advancement of knowledge and practice standards.

ACADEMIC CITATIONS

  • Dr. Aydın’s research has garnered significant academic attention, with numerous citations in prominent radiological journals. Her studies on abdominal and genitourinary radiology are referenced by other researchers and clinicians, indicating the high regard in which her work is held. This academic recognition is a testament to the quality and relevance of her research contributions.

LEGACY AND FUTURE CONTRIBUTIONS ON ENDOMETRIUM CANCER

  • Dr. Aydın’s legacy in the field of radiology is characterized by her dedication to advancing medical imaging and improving patient care. Looking ahead, she is poised to continue her impactful research and clinical work, with a focus on innovative imaging techniques and their applications in abdominal and genitourinary radiology. Her future contributions are expected to further enhance the understanding and practice of radiology, benefiting both the medical community and patients.

OTHER IMPORTANT TOPICS

TEACHING AND MENTORSHIP

  • In addition to her research and clinical responsibilities, Dr. Aydın is deeply committed to teaching and mentoring the next generation of radiologists. Her role at the University of Health Sciences allows her to shape the education and training of medical students and residents, ensuring the continued growth and development of the field.

COLLABORATIVE PROJECTS

  • Dr. Aydın actively engages in collaborative projects with other institutions and researchers. These collaborations enable the sharing of knowledge and expertise, fostering innovation and improving radiological practices globally. Her collaborative efforts have resulted in several joint publications and research initiatives.

PROFESSIONAL DEVELOPMENT

  • Continuous professional development is a cornerstone of Dr. Aydın’s career. She regularly participates in international conferences, workshops, and training programs to stay abreast of the latest advancements in radiology. This commitment to lifelong learning ensures that she remains at the forefront of her field, providing the highest standard of care to her patients.

 

📊🔬Notable Publication:

Extrapulmonary Tuberculosis: An Old but Resurgent Problem

  • Authors: Baykan, A.H., Sayiner, H.S., Aydin, E., Inan, I., Erturk, S.M.
    Journal: Insights into Imaging
  • Year: 2022

 

Quantitative Analysis of the Olfactory System in COVID-19: An MR Imaging Study

  • Authors: Altunisik, E., Baykan, A.H., Sahin, S., Aydin, E., Erturk, S.M.
    Journal: American Journal of Neuroradiology
  • Year: 2021

 

Primary Breast Tuberculosis: Imaging Findings of a Rare Disease

  • Authors: Baykan, A.H., Sayiner, H.S., Inan, I., Aydin, E., Erturk, S.M.
    Journal: Insights into Imaging
  • Year: 2021

 

Reliability of Real-Time Sonoelastography in the Diagnosis of Supraspinatus Tendinopathy

  • Authors: Aydın, E., Söylev, G.Ö., Muratlı, S.K., Tekindal, M.A., Ağıldere, M.
    Journal: Ultrasound Quarterly
  • Year: 2021

 

Optical Coherence Tomography-Angiography Findings of Prediabetic Patients

  • Authors: Emre, S., Altin, C., Ulusoy, M.O., Aydin, E.
    Journal: Oman Journal of Ophthalmology
  • Year: 2024

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Posted on by Pencis

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Guangxi Medical University Cancer Hospital | China

Author Profile

Scopus

Orcid id

🌟 Distinguished Scientist Award: Dr. Chen Wang 🌟

Full Name: Chen Wang
Gender: Male
Designation: Associate Research Fellow
Department: Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer
Institution/Organization: Guangxi Medical University Cancer Hospital
Qualification: Ph.D.
Area of Specialization: Oncology Therapeutics and Novel Approaches
Sub Division: Anti-tumor Nanomaterials

📚 Education and Experience

Born in Liaoning, China, in 1988, Dr. Chen Wang has dedicated his career to advancing cancer treatment through innovative research in materials science and engineering. He earned his BS (2010) and MS (2013) degrees from Shenyang University of Technology, followed by a Ph.D. from Harbin Engineering University in 2019. Dr. Wang’s postdoctoral research took place at the Changchun Institute of Applied Chemistry and Southern Medical University. He began his academic career at Jilin University of Chemical Technology and joined Guangxi Medical University Cancer Hospital in 2020, becoming an associate research fellow in 2022.

🧬 Research and Innovations

Dr. Wang specializes in the synthesis and clinical application of novel anti-tumor nanomaterials. His pioneering work on calcium overload as a novel treatment for tumor cells has garnered significant attention. The development of GMCP (GOx@MMPB@CaP-PEG) nanoparticles showcases his innovative approach, combining enhanced intratumor reactive oxygen species (ROS) levels with photothermal therapy to promote apoptosis in tumor cells.

🏆 Achievements

  • Publications: Nearly 30 SCI-indexed original articles, including 11 as first/corresponding author.
  • Projects: Completed 12 research projects, with 5 as the principal investigator.
  • Patents: Holds 7 patents.
  • Editorial Roles: Serves on the editorial boards and as a reviewer for multiple journals.
  • Memberships: Member of the China Food and Drug Enterprise Quality and Safety Promotion Association.
  • Citations: 495 citations in Scopus/Web of Science.
  • H-index: 13.
  • Impact Factor: Cumulative impact factor of 141.8 over the last three years.

Dr. Wang’s work in oncology therapeutics, particularly in anti-tumor nanomaterials, positions him as a leading figure in his field, making him a deserving recipient of the Distinguished Scientist Award.

🌐 Professional Links

📄 Certifications

  • Education Proof (Ph.D.): 1021722019110003
  • Government ID (Passport): E36369406

Dr. Chen Wang’s dedication to research, innovation, and the application of novel cancer treatments underscores his significant contributions to the field of oncology therapeutics.

 

📊🔬Notable Publication:

 

 

 

 

Dr. Lei Xia | Theranostics | Best Researcher Award

Posted on by Pencis

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD 🧬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
📞 Phone: 18811177191
✉️ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes 🩻
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes 🧫
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes 🧪
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) 🌟
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) 🌟
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) 🌟
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund 🌟
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund 🌟
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital 🌟
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund 🌟
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

📊🔬Notable Publication:

 

 

 

 

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION:

Citation: 08         Year: 2022

Citation: 01        Year: 2023

 

Prof. IsabellaCavalcanti – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof. IsabellaCavalcanti - Cancer Science - Best Researcher Award

Federal University of Pernambuco (UFPE) - Brazil

Author Profile

Google Scholar 

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Isabella Macário Ferro Cavalcanti began her academic journey by graduating in Biomedicine from the Federal University of Pernambuco (UFPE). Following this, she pursued a master's degree in Therapeutic Innovation at UFPE, delving into advanced studies in the field. She then proceeded to earn her doctorate in Biotechnology, further refining her expertise in biological sciences.

PROFESSIONAL ENDEAVORS

Dr. Cavalcanti's professional career has been marked by significant accomplishments. She specializes in Clinical Microbiology, obtaining further specialization at the University of Pernambuco (UPE). Currently, she serves as a professor at UFPE, where she contributes to the education and training of future professionals in the field. Her involvement extends to leadership roles within various post-graduate programs, emphasizing her dedication to academic advancement.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Cavalcanti's research endeavors are diverse and impactful. As the Head and Researcher of Clinical Microbiology at the Laboratory of Immunopathology Keizo Asami at UFPE (LIKA/UFPE), she spearheads investigations into drug delivery systems and their biological activities. Her research group, MicroNAT, focuses on innovative approaches to combat multi-drug-resistant bacteria and biofilm formation. Through her work, she seeks to advance pharmaceutical nanotechnology and fundamental microbiological understanding.

IMPACT AND INFLUENCE

Isabella Macário Ferro Cavalcanti's contributions have had a profound impact on the fields of pharmaceutical nanotechnology and microbiology. Her research findings contribute to the development of novel therapeutic strategies and the understanding of microbial resistance mechanisms. As a respected member of the Brazilian Society of Microbiology and various scientific committees, her expertise is recognized nationally and internationally.

ACADEMIC CITATIONS

Dr. Cavalcanti's work has garnered significant attention within the academic community, reflected in numerous citations of her research publications. Her contributions to scientific literature serve as a foundation for further exploration and innovation in the fields of biotechnology, microbiology, and drug delivery.

LEGACY AND FUTURE CONTRIBUTIONS

With a strong foundation in academia and research, Dr. Cavalcanti's legacy is marked by her dedication to advancing knowledge and addressing critical healthcare challenges. Her leadership in research groups and academic programs ensures the continued development of future scientists and the pursuit of innovative solutions to complex biomedical problems. As she continues her career, her contributions are poised to further shape the landscape of biomedicine and microbiology, leaving a lasting legacy of excellence and innovation.

NOTABLE PUBLICATIONS

Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria. 2024

Proteomic characterization and biological activities of the mucus produced by the zoanthid Palythoa caribaeorum (Duchassaing & Michelotti, 1860) 2023

Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. 2023

Gram-negative bacilli carrying mcr gene in Brazil: a pathogen on the rise. 2023

Antibiotic resistance profiles on pathogenic bacteria in the Brazilian environments. 2023

Prof Dr. ClausGarbe – Oncology Management and Prevention – Lifetime achievement Award

Posted on by Pencis

Prof Dr. ClausGarbe - Oncology Management and Prevention - Lifetime achievement Award

University of Tuebingen - Germany

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Professor Claus Garbe embarked on his academic journey by obtaining his MD from the Free University of Berlin in 1983. Following this, he pursued board certification in Dermatology and Venereology in 1987. His early academic pursuits laid the foundation for his subsequent groundbreaking work in dermatology and oncology.

PROFESSIONAL ENDEAVORS:

In 1990, Professor Garbe achieved his habilitation, akin to a PhD equivalent, with a focus on the biology of melanoma cells. This marked a significant milestone in his academic career, demonstrating his commitment to advancing the understanding of melanoma, a deadly form of skin cancer. In 1995, he transitioned to Eberhard Karls University, Tuebingen, where he assumed the role of University Professor of Dermatology and Head of the Division of Dermatooncology. This move expanded his scope of influence and provided a platform for furthering his research and clinical endeavors.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY MANAGEMENT AND PREVENTION

Professor Garbe's contributions to the field of dermatology and oncology are extensive and profound. His principal research interests encompass the biology and genetics of melanoma and keratinocyte skin cancers, therapeutic trials in skin diseases, epidemiologic studies, and dermato-histopathology. Through his pioneering research, he has elucidated crucial mechanisms underlying skin cancer development and progression, paving the way for innovative therapeutic approaches and preventive strategies.

IMPACT AND INFLUENCE:

Professor Garbe's impact on the field of dermatologic oncology is unparalleled. His leadership roles in numerous multicenter clinical trials since 1989 have facilitated the translation of research findings into clinical practice, ultimately improving patient outcomes. Moreover, his presidency of the European Association of Dermatologic Oncology (EADO) underscores his influence on a global scale, driving collaboration and innovation in the fight against skin cancer.

ACADEMIC CITATIONS:

With over 800 articles and 17 textbooks to his name, Professor Garbe's scholarly output is prolific. His impressive H-index of 116 points reflects the significant impact of his work within the scientific community. His research findings have been cited extensively, highlighting their relevance and contribution to advancing knowledge in dermatology and oncology.

LEGACY AND FUTURE CONTRIBUTIONS:

Professor Garbe's legacy is characterized by his unwavering dedication to advancing the field of dermatologic oncology. His contributions have not only expanded our understanding of skin cancer but have also shaped clinical practice and guidelines. As he continues to spearhead research efforts and mentor the next generation of scientists and clinicians, his legacy is poised to endure, leaving an indelible mark on the field for years to come.

NOTABLE PUBLICATIONS

Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients. 2024 (2)

Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia. 2024 (3)

Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. 2024 (1)

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. 2023 (6)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. 2023 (2)

Prof Dr. Nives Pećina-Šlaus – Cancer Genetics – Best Researcher Award

Posted on by Pencis

Prof Dr. Nives Pećina-Šlaus - Cancer Genetics - Best Researcher Award

Department of Biology School of Medicine University of Zagreb - Croatia

AUTHOR PROFILE 

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Nives Pecina-Slaus embarked on her academic journey at the University of Zagreb, where she earned her Bachelor's and Master's degrees in Biology in 1990 and 1992, respectively. Her scholarly pursuits culminated in a Ph.D. in the field of molecular oncology from the Medical School at the University of Zagreb in 1998. During her education, she underwent training at prestigious institutions including the Cold Spring Harbor Laboratory in New York and Georgetown University in Washington DC, USA.

PROFESSIONAL ENDEAVORS

Pecina-Slaus's professional career is distinguished by her role as a tenured professor at the Department of Biology and Head of the Laboratory of Neuro-oncology at the Croatian Institute for Brain Research within the School of Medicine at the University of Zagreb. She has served as the principal investigator on seven scientific projects, demonstrating her leadership in the field. Moreover, her research has yielded significant contributions, with over 100 publications to her credit, including scientific papers, book chapters, and a book. Her primary research interests encompass cancer genetics, the Wnt signaling pathway, epithelial to mesenchymal transition, brain tumorigenesis, tumor suppressor genes, and oncogenes.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Pecina-Slaus's work has contributed extensively to our understanding of neuro-oncology and related fields. Her research has shed light on crucial mechanisms underlying cancer development and progression, particularly in the context of brain tumors. Through her numerous publications, she has disseminated valuable insights into cancer genetics, signaling pathways, and tumor microenvironment dynamics. Her expertise extends to mentorship, where she has guided numerous students in their theses.

IMPACT AND INFLUENCE

Pecina-Slaus's contributions have garnered widespread recognition in the scientific community, as evidenced by her invitations to speak at 25 meetings. Furthermore, her work has had a substantial impact on the academic community, as reflected in her impressive citation metrics. With over 2600 citations on Google Scholar and notable indices on Scopus and Web of Science, she has established herself as a respected authority in her field.

ACADEMIC LEGACY AND FUTURE CONTRIBUTIONS

Pecina-Slaus's legacy is marked by her prolific research output, mentorship of students, and editorial roles in esteemed scientific journals. Her dedication to advancing knowledge in neuro-oncology and related disciplines has earned her numerous awards and accolades, including recognition from the Croatian Medical Association and the Academy of Medical Sciences. Moving forward, she is poised to continue making significant contributions to the field through her research, teaching, and editorial activities, further solidifying her position as a leader in neuro-oncology research.

NOTABLE PUBLICATIONS

Glioma Stem Cells—Features for New Therapy Design. 2024

Genetics in ophthalmology: molecular blueprints of retinoblastoma. 2023 (3)

Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. 2023 (6)

Different Approaches to Study Molecular Blueprint and Biological Behavior of Brain Tumors: Editorial to the Special Issue “Advances in Molecular Genetics of Brain Tumors”. 2023

Bilateral Meningioma: A Case Report and Review of the Literature. 2022 (2)